

To whom it may concern:

It has been rumored that apixaban will not be on the preferred drug list for Iowa Medicaid.

In my opinion, this is a unique novel anticoagulant with excellent efficacy and lower risk of adverse events, specifically bleeding. I would hope the P&T committee would make every effort to have it included as an option for the patients we serve.

Thanks for your consideration.